TTRX Turn Therapeutics Inc.
Fundamentals / CIK 0002023016 / USDTurn Therapeutics Inc. reported $16.35M in total assets and a net loss of $12.77M through December 31, 2025 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open TTRX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025-- Dec 31, 2025
-
Operating Income FY 2025-$7.05M Operating profit
-
Net Income FY 2025-$12.77M GAAP bottom line
-
Diluted EPS FY 2025-$0.42 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$9.43M Total debt: $6.23M
Annual revenue and net income
2 fiscal years (2024 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 |
|---|---|---|
| Research & Development | $266K | $246K |
| Total Operating Expenses | $5.86M | $1.80M |
| Operating Income | -$5.86M | -$1.80M |
| EBITDA | -$5.81M | -$1.75M |
| Interest Income | $30K | $29K |
| Net Income | -$3.19M | -$1.77M |
| Basic EPS | -$0.12 | -$0.07 |
| Diluted EPS | -$0.12 | -$0.07 |
| Basic Shares Outstanding | 27.7M | 26.6M |
| Diluted Shares Outstanding | 27.7M | 26.6M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Research & Development | $605K | $475K | $109K | $35K | $159K | $63K | $9.3K | $153K |
| Total Operating Expenses | $1.98M | $1.63M | $1.25M | $2.19M | $1.91M | $1.37M | $385K | $673K |
| Operating Income | -$1.98M | -$1.63M | -$1.25M | -$2.19M | -$1.91M | -$1.37M | -$385K | -$673K |
| Interest Income | $84K | -- | $50K | $14K | $5.1K | -- | $5.2K | $6.5K |
| Interest Expense | $341K | -- | -- | -- | -- | -- | -- | -- |
| Net Income | -$6.23M | -$5.85M | -$971K | $279K | -$1.90M | -$1.24M | -$329K | -$666K |
| Basic EPS | -$0.21 | -$0.20 | -$0.03 | -- | -$0.07 | -$0.05 | -$0.01 | -$0.03 |
| Diluted EPS | -$0.21 | -$0.20 | -$0.03 | -- | -$0.07 | -$0.05 | -$0.01 | -$0.03 |
| Basic Shares Outstanding | 30.1M | 29.8M | 29.5M | -- | 28.0M | 27.5M | 27.0M | 26.6M |
| Diluted Shares Outstanding | 30.1M | 29.8M | 29.5M | -- | 28.0M | 27.5M | 27.0M | 26.6M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 |
|---|---|---|
| Cash & Cash Equivalents | $4.03M | $498K |
| Cash & Short-Term Investments | $4.03M | $498K |
| Total Current Assets | $5.20M | $1.10M |
| Intangible Assets | $922K | $822K |
| Total Non-Current Assets | $6.97M | $951K |
| Total Assets | $12.16M | $2.05M |
| Total Current Liabilities | $6.00M | $708K |
| Deferred Revenue (Non-Current) | $1.44M | $1.44M |
| Total Non-Current Liabilities | $1.47M | $1.52M |
| Total Liabilities | $7.48M | $2.23M |
| Total Debt (incl. Leases) | $80K | $121K |
| Common Stock | $2.9K | $2.7K |
| Retained Earnings | -$22.39M | -$19.20M |
| Total Stockholders' Equity | $4.69M | -$177K |
| Total Equity | $4.69M | -$177K |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $9.43M | $9.95M | $11.01M | $4.03M | $514K | $498K |
| Cash & Short-Term Investments | $9.43M | $9.95M | $11.01M | $4.03M | $514K | $498K |
| Total Current Assets | $11.08M | $10.43M | $11.45M | $5.20M | $3.29M | $1.10M |
| Intangible Assets | $913K | $911K | $920K | $922K | $905K | $822K |
| Total Non-Current Assets | $5.27M | $6.53M | $7.19M | $6.97M | $1.00M | $951K |
| Total Assets | $16.35M | $16.96M | $18.64M | $12.16M | $4.30M | $2.05M |
| Short-Term Debt | $444K | -- | -- | -- | -- | -- |
| Total Current Liabilities | $3.48M | $8.76M | $5.13M | $6.00M | $2.31M | $708K |
| Long-Term Debt | $5.74M | $6.06M | $5.94M | -- | -- | -- |
| Deferred Revenue (Non-Current) | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M | $1.44M |
| Total Non-Current Liabilities | $7.18M | $7.51M | $7.40M | $1.47M | $1.48M | $1.52M |
| Total Liabilities | $10.66M | $16.27M | $12.53M | $7.48M | $3.79M | $2.23M |
| Total Debt (incl. Leases) | $6.23M | $6.12M | $6.01M | $80K | $91K | $121K |
| Common Stock | $3.1K | $3.0K | $3.0K | $2.9K | $2.8K | $2.7K |
| Retained Earnings | -$35.44M | -$29.21M | -$23.36M | -$22.39M | -$22.67M | -$19.20M |
| Total Stockholders' Equity | $5.69M | $687K | $6.12M | $4.69M | $504K | -$177K |
| Total Equity | $5.69M | $687K | $6.12M | $4.69M | $504K | -$177K |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 |
|---|---|---|
| Net Income | -$3.19M | -$1.77M |
| Depreciation & Amortization | $53K | $47K |
| Stock-Based Compensation | $419K | $353K |
| Operating Cash Flow | -$2.56M | -$1.36M |
| Investing Cash Flow | -$153K | -$99K |
| Common Stock Issued | $6.92M | $1.15M |
| Financing Cash Flow | $6.92M | $1.15M |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$6.23M | -$5.85M | -$971K | $279K | -$1.90M | -$1.24M | -$329K | -$666K |
| Stock-Based Compensation | $713K | $419K | $281K | $256K | $39K | $47K | $77K | -- |
| Operating Cash Flow | -$1.55M | -$923K | -$1.63M | -$1.18M | -$589K | -$500K | -$298K | -- |
| Investing Cash Flow | -$16K | -$5.8K | -$12K | -- | -- | -- | -- | -- |
| Common Stock Issued | -- | -- | -- | $3.77M | $0 | $2.15M | $998K | -- |
| Financing Cash Flow | $1.64M | $1 | $7.79M | $3.18M | $595K | $2.15M | $998K | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 |
|---|---|---|
| Return on Equity (ROE) | -68.2% | -- |
| Return on Assets (ROA) | -26.3% | -86.3% |
| Current Ratio | 0.87x | 1.55x |
| Quick Ratio | 0.67x | 0.70x |
| Debt to Equity | 0.02x | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -224.4% | -1229.6% | -62.7% | -68.2% | -- | -- | -- | -- |
| Return on Assets (ROA) | -78.1% | -49.8% | -20.6% | -26.3% | -- | -- | -- | -- |
| Current Ratio | 3.19x | 1.19x | 2.23x | 0.87x | 1.43x | -- | -- | -- |
| Quick Ratio | 2.71x | 1.14x | 2.15x | 0.67x | 0.22x | -- | -- | -- |
| Debt to Equity | 1.09x | 8.91x | 0.98x | 0.02x | 0.18x | -- | -- | -- |